Skip to main content
OpenTrials
Completed

NCT Number: NCT02392806

Comparative Effectiveness Study of Bubble CPAP Devices in the NICU

Multiple different devices are available to provide Bubble CPAP to preterm and newborn infants. The most significant difference between these devices is the size of the bubble produced by the exhalation limb. This study will determine if one Bubble CPAP device (BabiPlus vs B&B) is more effective in improving oxygenation and decreasing extubation failure in the extremely low birthweight population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–100 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cardinal Glennon Children's Hospital

St Louis, Missouri, 63104, United States

About this study

Primary outcome: Bubble CPAP failure (re-intubation or use of non-invasive positive pressure ventilation) within 72 hours following extubation Secondary outcome: Number of infants that reach 21% inspired oxygen during initial study period Secondary outcome: Apnea/bradycardia events in the initial study period Secondary outcome: Mean oxygen requirement following initial study period

Population: Infants born at <=1250 grams birth weight but >= 500 grams birth weight

Randomization: Equal allocation stratified by gestational age (<27 weeks, >=27 weeks)

Study diagram:

72h 24h X---------->X1----------->Y2 Y---------->Y1----------->X2 Infants will be randomly assigned to treatment X (BabiPlus, control group) or treatment Y (B&B Bubbler, intervention group). The primary outcome is bubble CPAP failure during the first 72 hours following extubation, measured at time point 1 in the diagram. Bubble CPAP failure is defined as requiring re-intubation or non-invasive positive pressure ventilation (NIPPV), requiring FiO2 of >60% for one hour or a pCO2 measurement of >65 mm Hg. For those infants that remain on CPAP during the initial study period, the number that reach 21% inspired oxygen for >12 consecutive hours will be compared between groups. This difference will also be analyzed using a Chi square test.

Those infants that remain on CPAP following the 72 hour initial study period (e.g., did not meet primary outcome criteria) will be crossed over to the opposite treatment arm for at least 24 hours. The minimum oxygen requirement required to keep the saturations in the ordered range, per standard NICU guidelines, will be recorded and compared between time points 1 and 2.

This study design is complex due to the nature of the disease of these patients. Each day every infant's premature pulmonary disease is evolving. There is no way to control for this.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infant delivered at >=500 grams and <=1250 grams birth weight.
  • Infant requires intubation for mechanical ventilation within the first 48 hours following delivery.
  • Infant has received exogenous surfactant during mechanical ventilation.

Exclusion criteria

  • Decision by attending physician to redirect to comfort care
  • Congenital condition that precludes the use of CPAP (choanal atresia, diaphragmatic hernia, etc.)
  • Birth weight >1250 grams or <500 grams.
  • Non-English speaking parents. -

Treatment and study plan

Bubble CPAP- BabiPlus, Respiralogics

Device

Infant will be randomized to BabiPlus Bubbler at time of extubation

Other names: Bubble Continuous Positive Airway Pressure (BCPAP)

Bubble CPAP- B&B Bubbler, B&B Medical devices

Device

Infant will be randomized to B&B Bubbler at time of extubation

Primary outcomes

  1. Number of Participants With Extubation Failure

    Time frame: Within 72 hours of extubation

    Bubble CPAP failure (re-intubation or use of non-invasive positive pressure ventilation) within 72 hours following extubation

Secondary outcomes

  1. Oxygenation - Oxygen Saturation Via Pulse Oximetry Recorded Hourly

    Time frame: 96 hours

    Number of infants that reach 21% inspired oxygen during initial study period of 72 hours plus the crossover period of 24 hours

Sponsors and collaborators

Lead sponsor

Marya Strand, MD

Other

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Mar 19, 2015
Registry last updated
Mar 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.